Härter Martin, Bartsch Anna-Lena, Egger Nina, König Hans-Helmut, Kriston Levente, Schulz Holger, Tiemann Michael, Brütt Anna Levke, Buchholz Angela
Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Trials. 2015 Oct 9;16:447. doi: 10.1186/s13063-015-0977-6.
Tobacco consumption is a preventable risk factor for chronic disease and complicates the treatment of medical conditions. Therefore, the German health insurance company AOK NORDWEST has developed a collaborative smoking cessation intervention for individuals with cardiovascular disease, chronic obstructive pulmonary disease and heavy smokers, with the aim of reducing tobacco consumption. The objective of the study ENTER is to evaluate the effectiveness of the collaborative smoking cessation intervention and determine its cost-effectiveness.
METHODS/DESIGN: This study is a cluster-randomized controlled trial conducted with 40 medical practices that are being selected from different geographic regions in Germany. Participating medical practices will be randomly allocated to either the intervention or control group. Within the medical practices, a total of 800 patients will be recruited for participation in the study and blinded to group assignment. Patients are included in the study if they are 18 years or older, insured by AOK, heavy smokers (smoke at least 20 cigarettes per day) and/or suffer from chronic obstructive pulmonary disease or cardiovascular disease. Exclusion criteria are patients who are nonsmokers, who have cognitive impairments or who are illiterate. Physicians from medical practices in the intervention group will motivate patients to participate in a smoking cessation program offered by the health insurance, refer them to the program and ask about their program participation. Physicians from medical practices in the control group will provide usual care. Data collection will take place on the date of study inclusion and after 6 and 12 months. The primary outcome is the amount of cigarettes consumed during the past 30 days, 12 months after the initial medical consultation. Secondary outcomes are abstinence from smoking, health-related quality of life and respiratory complaints. Moreover, a process evaluation and health economic analysis will be performed.
The results of this study will help to determine whether the collaborative smoking cessation intervention is an effective and feasible way to promote smoking cessation in the primary care setting and provide evidence regarding its cost-effectiveness.
German Clinical Trials Register DRKS00006079 . Registered 4 June 2014.
烟草消费是慢性病的一个可预防风险因素,会使医疗状况的治疗变得复杂。因此,德国健康保险公司北威州AOK为患有心血管疾病、慢性阻塞性肺疾病的患者以及重度吸烟者制定了一项联合戒烟干预措施,旨在减少烟草消费。ENTER研究的目的是评估联合戒烟干预措施的有效性,并确定其成本效益。
方法/设计:本研究是一项整群随机对照试验,在德国不同地理区域选取了40家医疗诊所进行。参与的医疗诊所将被随机分配到干预组或对照组。在这些医疗诊所内,总共将招募800名患者参与研究,且患者对分组情况不知情。年龄在18岁及以上、由北威州AOK承保、重度吸烟者(每天至少吸20支烟)和/或患有慢性阻塞性肺疾病或心血管疾病的患者被纳入研究。排除标准为不吸烟的患者、有认知障碍的患者或文盲患者。干预组医疗诊所的医生将激励患者参与健康保险公司提供的戒烟项目,将他们转介到该项目并询问他们参与项目的情况。对照组医疗诊所的医生将提供常规护理。数据收集将在研究纳入之日以及6个月和12个月后进行。主要结局是初次就诊后12个月内过去30天的吸烟量。次要结局是戒烟情况、健康相关生活质量和呼吸道症状。此外,还将进行过程评估和健康经济分析。
本研究结果将有助于确定联合戒烟干预措施是否是在初级保健环境中促进戒烟的有效且可行的方法,并提供有关其成本效益的证据。
德国临床试验注册中心DRKS00006079。2014年6月4日注册。